Reassigned surgical margins after neoadjuvant chemotherapy results in low local recurrence in dogs with mast cell tumours.
Journal
The Veterinary record
ISSN: 2042-7670
Titre abrégé: Vet Rec
Pays: England
ID NLM: 0031164
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
revised:
09
05
2024
received:
06
02
2024
accepted:
30
07
2024
medline:
12
9
2024
pubmed:
12
9
2024
entrez:
12
9
2024
Statut:
aheadofprint
Résumé
Neoadjuvant chemotherapy (NAC) is delivered before surgery to allow less extensive tumour resection, but the optimal surgical margin width after NAC is unknown. The aim of this study was to determine the impact of reassigned margins on local recurrence after NAC in dogs with mast cell tumours (MCTs). A retrospective analysis was conducted for dogs with MCTs undergoing NAC consisting of vinblastine and prednisolone, subsequent tumour resection and lymphadenectomy, and a minimum follow-up of 6 months. Surgical margins were reassigned based on the size of the MCT after NAC. Pre- and post-NAC measurements of MCTs were recorded. The margin status was assessed with a combined radial and tangential sectioning technique; pre-NAC MCT cytograde and lymph node (LN) cytological status were compared with the Kiupel grade and Weishaar stage, respectively. Twenty-two dogs were included. MCT shrinkage after NAC consistently occurred, with a median reduction rate of 40.4% (range 5%-94.5%). Margins were complete in 15 of 22 dogs, and two MCTs and three LNs appeared histologically downgraded and downstaged, respectively. Two (9.1%) MCTs recurred. The limitations of this study were the small sample size and relatively short follow-up. NAC leads to shrinkage of canine MCTs, with the resulting reassigned surgical margins being associated with a low recurrence rate.
Sections du résumé
BACKGROUND
BACKGROUND
Neoadjuvant chemotherapy (NAC) is delivered before surgery to allow less extensive tumour resection, but the optimal surgical margin width after NAC is unknown. The aim of this study was to determine the impact of reassigned margins on local recurrence after NAC in dogs with mast cell tumours (MCTs).
METHODS
METHODS
A retrospective analysis was conducted for dogs with MCTs undergoing NAC consisting of vinblastine and prednisolone, subsequent tumour resection and lymphadenectomy, and a minimum follow-up of 6 months. Surgical margins were reassigned based on the size of the MCT after NAC. Pre- and post-NAC measurements of MCTs were recorded. The margin status was assessed with a combined radial and tangential sectioning technique; pre-NAC MCT cytograde and lymph node (LN) cytological status were compared with the Kiupel grade and Weishaar stage, respectively.
RESULTS
RESULTS
Twenty-two dogs were included. MCT shrinkage after NAC consistently occurred, with a median reduction rate of 40.4% (range 5%-94.5%). Margins were complete in 15 of 22 dogs, and two MCTs and three LNs appeared histologically downgraded and downstaged, respectively. Two (9.1%) MCTs recurred.
LIMITATIONS
CONCLUSIONS
The limitations of this study were the small sample size and relatively short follow-up.
CONCLUSION
CONCLUSIONS
NAC leads to shrinkage of canine MCTs, with the resulting reassigned surgical margins being associated with a low recurrence rate.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e4595Informations de copyright
© 2024 British Veterinary Association.
Références
Marcovitch H. Black's medical dictionary. 43rd ed. London: Bloomsbury Information; 2017.
West HJ, Jin J. JAMA oncology patient page. Neoadjuvant therapy. JAMA Oncol. 2015;1(4):550.
Bacci G, Picci P, Ferrari S, Ruggieri P, Casadei R, Tienghi A, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer. 1993;72(11):3227–3238.
Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672–2685.
Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, et al. A randomized controlled trial of octreotide pamoate long‐acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin‐like growth factor suppression and chemotherapy. Clin Cancer Res. 2002;8(7):2406–2412.
Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T. Adjuvant and neoadjuvant cancer therapies: a historical review and a rational approach to understand outcomes. Semin Oncol. 2019;46(1):83–99.
O'Donnell PW, Manivel CJ, Cheng EY, Clohisy DR. Chemotherapy influences the pseudocapsule composition in soft tissue sarcomas. Clin Orthop Relat Res. 2014;472(3):849–855.
Cloyd JM, Heh V, Pawlik TM, Ejaz A, Dillhoff M, Tsung A, et al. Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta‐analysis of randomized controlled trials. J Clin Med. 2020;9(4):1129.
Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta‐analysis. J Natl Cancer Inst. 2005;97:188–194.
Bray J, Polton G. Neoadjuvant and adjuvant chemotherapy combined with anatomical resection of feline injection‐site sarcoma: results in 21 cats. Vet Comp Oncol. 2016;14(2):147–160.
Stanclift RM, Gilson SD. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. J Am Vet Med Assoc. 2008;232(1):53–62.
Linde KJ, Stockdale SL, Mison MB, Perry JA. The effect of prednisone on histologic and gross characteristics in canine mast cell tumors. Can Vet J. 2021;62(1):45.
Klahn S, Dervisis N, Lahmers K, Benitez M. Evaluation of tumor grade and proliferation indices before and after short‐course anti‐inflammatory prednisone therapy in canine cutaneous mast cell tumors: a pilot study. Vet Sci. 2022;9(6):277.
Ossowska M, Picornell JA, Finotello R, Amores‐Fuster I, Tanis J‐B. Pre‐operative neoadjuvant vinblastine‐prednisolone in canine mast cell tumours: a single‐centre retrospective cohort study. Vet Comp Oncol. 2023;21(3):447–459.
Guerra D, Faroni E, Sabattini S, Agnoli C, Chalfon C, Stefanello D, et al. Histologic grade has a higher‐weighted value than nodal status as predictor of outcome in dogs with cutaneous mast cell tumours and overtly metastatic sentinel lymph nodes. Vet Comp Oncol. 2022;20(3):551–558.
Isaji S, Mizuno S, Windsor JA, Bassi C, Fernández‐Del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2–11.
Heinemann V, Haas M, Boeck S. Neoadjuvant treatment of borderline resectable and non‐resectable pancreatic cancer. Ann Oncol. 2013;24(10):2484–2492.
Camus MS, Priest HL, Koehler JW, Driskell EA, Rakich PM, Ilha MR, et al. Cytologic criteria for mast cell tumor grading in dogs with evaluation of clinical outcome. Vet Pathol. 2016;53(6):1117–1123.
Krick EL, Billings AP, Shofer FS, Watanabe S, Sorenmo KU. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. Vet Comp Oncol. 2009;7(2):130–138.
Marconato L, Stefanello D, Solari Basano F, Faroni E, Dacasto M, Giantin M, et al. Subcutaneous mast cell tumours: a prospective multi‐institutional clinicopathological and prognostic study of 43 dogs. Vet Rec. 2023;193(1):e2991.
Veterinary co‐operative oncology group. Common terminology criteria for adverse events (VCOG‐CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2016;14(4):417–446.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–216.
Pratschke KM, Atherton MJ, Sillito JA, Lamm CG. Evaluation of a modified proportional margins approach for surgical resection of mast cell tumors in dogs: 40 cases (2008‒2012). J Am Vet Med Assoc. 2013;243(10):1436–1441.
Itoh T, Kojimoto A, Uchida K, Chambers J, Shii H. Long‐term postsurgical outcomes of mast cell tumors resected with a margin proportional to the tumor diameter in 23 dogs. J Vet Med Sci. 2021;83(2):230–233.
Saunders H, Thomson MJ, O'Connell K, Bridges JP, Chau L. Evaluation of a modified proportional margin approach for complete surgical excision of canine cutaneous mast cell tumours and its association with clinical outcome. Vet Comp Oncol. 2021;19(4):604–615.
Follette CM, Giuffrida MA, Balsa IM, Culp WTN, Mayhew PD, Oblak ML, et al. A systematic review of criteria used to report complications in soft tissue and oncologic surgical clinical research studies in dogs and cats. Vet Surg. 2020;49(1):61–69.
Sabattini S, Brocanelli A, Zaccone R, Faroni E, Renzi A, Ciammaichella L, et al. The two‐tier grading system identifies canine cutaneous and/or subcutaneous mast cell tumors with aggressive biological behavior regardless of growth model. Vet Pathol. 2024:3009858241240443.
Kiupel M, Webster JD, Bailey KL, Best S, Delay J, Detrisac CJ, et al. Proposal of a 2‐tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol. 2011;48(1):147–155.
Smith J, Kiupel M, Farrelly J, Cohen R, Olmsted G, Kirpensteijn J, et al. Recurrence rates and clinical outcome for dogs with grade II mast cell tumours with a low AgNOR count and Ki67 index treated with surgery alone. Vet Comp Oncol. 2017;15(1):36–45.
Sabattini S, Faroni E, Renzi A, Ghisoni G, Rigillo A, Bettini G, et al. Longitudinal lymph node step‐sectioning for the identification of metastatic disease in canine mast cell tumor. Vet Pathol. 2022;59(5):768–772.
Weishaar KM, Thamm DH, Worley DR, Kamstock DA. Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumour and a proposed classification system for the evaluation of node metastasis. J Comp Pathol. 2014;151(4):329–338.
Murphy S, Sparkes AH, Brearley MJ, Smith KC, Blunden AS. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and the efficacy of surgical resection. Vet Rec. 2004;154(24):743–746.
Donnelly L, Mullin C, Balko J, Goldschmidt M, Krick E, Hume C, et al. Evaluation of histological grade and histologically tumour‐free margins as predictors of local recurrence in completely excised canine mast cell tumours. Vet Comp Oncol. 2015;13(1):70–76.
Séguin B, Besancon MF, McCallan JL, Dewe LL, Tenwolde MC, Wong EK, et al. Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994‒2002). J Vet Intern Med. 2006;20(4):933–940.
Vincenti S, Findji F. Influence of treatment on the outcome of dogs with incompletely excised grade‐2 mast cell tumors. Schweiz Arch Tierheilkd. 2017;159(3):171–177.
Wustefeld‐Janssens B, Smith L, Wilson‐Robles H. Neoadjuvant chemotherapy and radiation therapy in veterinary cancer treatment: a review. J Small Anim Pract. 2021;62(4):237–243.
Iodence AE, Wallace ML, Grimes JA, Schmiedt CW. Dogs undergoing surgical excision of mast cell tumors are not at increased risk of incisional complications. J Am Vet Med Assoc. 2022;260(1):88–95.